English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 904051      Online Users : 817
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14732


    Title: Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression
    Authors: Liu, TH;Chen, SC;Rau, KM;Lu, LC;Lin, PT;Su, YY;Teng, W;Lai, SW;Yehn, RH;Kao, TM;Lee, PC;Wu, CJ;Chen, CH;Hsu, CH;Lin, SM;Huang, YH;Chen, LT;Cheng, AL;Shen, YC
    Contributors: National Institute of Cancer Research
    Abstract: Background: Increasingly more patients with ad-vanced hepatocellular carcinoma (HCC) achieve du-rable response (DR) with immune checkpoint inhibitor (ICI)-based immunotherapy. The objective of this study is to characterize the progression patterns, dispositions, and outcomes of a large group of real-world durable responders. Methods: This is a retrospective analysis involving 8 major referral medical centers in Taiwan. Patients with advanced HCC who received ICI-based immunotherapy and achieved DR were included for anal-ysis. DR was defined as partial response (PR) or stable disease (SD) per RECIST1.1 for more than 8 months after initiation of immunotherapy. Oligoprogression and polyprogression were defined as progression at ≤3 and >3 lesions, respectively. Locoregional therapy (LRT) herein included surgery, ablation, transarterial chemoembolization, yttrium-90 radioembolization, ra-diotherapy, and hepatic arterial infusion chemotherapy. Overall survival (OS) was defined as the time from the initiation of immunotherapy to death of any causes. Results: From August 2015 to March 2021, 91 durable responders (63 PR and 28 SD) were identified. Median age was 62.0 years. Most of them were male (n=69, 75.8%) and with chronic viral hepatitis (n=69, 75.8%).
    Date: 2022-10
    Relation: Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412.
    Link to: https://doi.org/10.1002/hep.32697
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0270-9139&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000870796604274
    Appears in Collections:[陳立宗] 會議論文/會議摘要
    [蘇勇曄] 會議論文/會議摘要

    Files in This Item:

    File Description SizeFormat
    ISI000870796604274.pdf1939KbAdobe PDF133View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback